A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
Status:
Completed
Trial end date:
2021-04-08
Target enrollment:
Participant gender:
Summary
This is a study for participants with type 2 diabetes mellitus. The main purpose of this
study is to learn more about how tirzepatide and placebo affect the body's ability to respond
to blood sugar levels after a meal. The study will last up to 38 weeks, including a 28-week
treatment period.